Feb 10, 2022 / 03:00AM GMT
Operator
Ladies and gentlemen, welcome to the Quarter 3 FY '22 Earnings Conference Call of Aurobindo Pharma Limited. (Operator Instructions). I now hand the conference over to Mr. Arvind Bothra. Thank you, and over to you, sir.
Arvind Bothra - Aurobindo Pharma Limited - Head of IR & Corporate Communications
Thank you, Aditya. Good morning, and a warm welcome to our third quarter FY '22 earnings call. I'm Arvind Bothra from the Investor Relations team. We hope you have received the Q3 FY '22 financials and the press release that we -- was sent out yesterday. These are also available on our website.
I would like to introduce my senior management team today on the call with us, represented by Mr. P.V. Ram Prasad Reddy, Chairman, Aurobindo Pharma USA; Mr. K. Nithyananda Reddy, Vice Chairman and Managing Director of Aurobindo Pharma Limited; Mr. Santhanam Subramanian, CFO; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialties Limited, the entity housing Aurobindo's sterile and generic injectable products, oncology and hormonal oral business. And we also have on
Q3 2022 Aurobindo Pharma Ltd Earnings Call Transcript
Feb 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers